Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Daniel Ruderman"'
Autor:
Nikhil Naik, Ali Madani, Andre Esteva, Nitish Shirish Keskar, Michael F. Press, Daniel Ruderman, David B. Agus, Richard Socher
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-8 (2020)
Determination of estrogen receptor status (ERS) in breast cancer tissue requires immunohistochemistry, which is sensitive to the vagaries of sample processing and the subjectivity of pathologists. Here the authors present a deep learning model that d
Externí odkaz:
https://doaj.org/article/169f3fde02b44f04a44160ad8fb94419
Autor:
Katherin Patsch, Naim Matasci, Anjana Soundararajan, Patricia Diaz, David B. Agus, Daniel Ruderman, Mitchell E. Gross
Publikováno v:
BMC Research Notes, Vol 12, Iss 1, Pp 1-7 (2019)
Abstract Objective Cell-free DNA (cfDNA) is an attractive cancer biomarker, as it is thought to reflect a component of the underlying genetic makeup of the tumor and is readily accessible in serial fashion. Because chemotherapy regimens are expected
Externí odkaz:
https://doaj.org/article/b6b28c1fefbe4213905ffdd9b4b4e7d9
Autor:
Michael F. Press, Ali Madani, Nitish Shirish Keskar, David B. Agus, Daniel Ruderman, Nikhil Naik, Richard Socher, Andre Esteva
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-8 (2020)
Nature Communications
Nature Communications
For newly diagnosed breast cancer, estrogen receptor status (ERS) is a key molecular marker used for prognosis and treatment decisions. During clinical management, ERS is determined by pathologists from immunohistochemistry (IHC) staining of biopsied
Autor:
Ellen G. Cohn, Daniel Ruderman
Publikováno v:
The Journal of Primary Prevention
Although researchers have found support for a relationship between temperature and violence and evidence of temporal patterns in violent crime, research on homicide shows less consistent results and no research on mass murder has been conducted. We a
Autor:
Darryl Shibata, Fei Sha, Rishi R. Rawat, Daniel Ruderman, Preeyam Roy, David B. Agus, Itzel Ortega
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-13 (2020)
Scientific Reports
Scientific Reports
Because histologic types are subjective and difficult to reproduce between pathologists, tissue morphology often takes a back seat to molecular testing for the selection of breast cancer treatments. This work explores whether a deep-learning algorith
Autor:
Patricia M Diaz, Katherin Patsch, Daniel Ruderman, Mitchell E. Gross, Naim Matasci, David B. Agus, Anjana Soundararajan
Publikováno v:
BMC Research Notes, Vol 12, Iss 1, Pp 1-7 (2019)
BMC Research Notes
BMC Research Notes
Objective Cell-free DNA (cfDNA) is an attractive cancer biomarker, as it is thought to reflect a component of the underlying genetic makeup of the tumor and is readily accessible in serial fashion. Because chemotherapy regimens are expected to act ra
Autor:
Grzegorz Zapotoczny, Katherin Patsch, Ren X. Sun, Mayada Aljehani, Jerry S.H. Lee, Charles E. McKenna, Chen Yu, David B. Agus, Yuanye Sun, Nolan Ung, Bethany Haliday, Harish Sura, Boris A. Kashemirov, Chao Liu, Daniel Ruderman
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America
Small molecules that target the androgen receptor (AR) are the mainstay of therapy for lethal castration-resistant prostate cancer (CRPC), yet existing drugs lose their efficacy during continued treatment. This evolution of resistance is due to heter
Autor:
Paul Macklin, Daniel Ruderman, Shannon M. Mumenthaler, Matthew Brovold, Ahmadreza Ghaffarizadeh, David B. Agus, Roy Lau, Shay Soker, Edwin F. Juarez, Dipen Vyas, Anthony Atala, Chun-Te Chiang
Publikováno v:
GigaScience
Background Colorectal cancer (CRC) mortality is principally due to metastatic disease, with the most frequent organ of metastasis being the liver. Biochemical and mechanical factors residing in the tumor microenvironment are considered to play a pivo
Autor:
Alexandra N. Demetriou, Niharika Choudhury, Chun-Te Chiang, Nolan Ung, Shannon M. Mumenthaler, Daniel Ruderman, Kimya Ghaffarian
Publikováno v:
Cancer letters
Non-small cell lung cancer (NSCLC) patients with activating EGFR mutations are often successfully treated with EGFR tyrosine kinase inhibitor (TKI) such as erlotinib; however, treatment resistance inevitably occurs. Given tumor metabolism of glucose
Autor:
Richard S. Gaster, Sanjiv S. Gambhir, Hui Yen Chuang, Shan X. Wang, Carmel T. Chan, Daniel Ruderman, Parag Mallick, Jung Rok Lee, Michelle Atallah, Scott W. Lowe
Publikováno v:
Nano Letters. 17:6644-6652
Each immunoglobulin isotype has unique immune effector functions. The contribution of these functions in the elimination of pathogens and tumors can be determined by monitoring quantitative temporal changes in isotype levels. Here, we developed a nov